Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Non-Current Assets (2016 - 2025)

AC Immune (ACIU) has disclosed Non-Current Assets for 9 consecutive years, with $67.3 million as the latest value for Q4 2024.

  • On a quarterly basis, Non-Current Assets rose 3.47% to $67.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $67.3 million, a 3.47% increase, with the full-year FY2024 number at $67.3 million, up 4.76% from a year prior.
  • Non-Current Assets was $67.3 million for Q4 2024 at AC Immune, up from $65.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $67.3 million in Q4 2024 to a low of $7.7 million in Q4 2020.
  • A 5-year average of $52.8 million and a median of $63.8 million in 2021 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: skyrocketed 726.87% in 2021, then decreased 5.86% in 2022.
  • AC Immune's Non-Current Assets stood at $7.7 million in 2020, then surged by 726.87% to $63.8 million in 2021, then decreased by 5.86% to $60.0 million in 2022, then increased by 8.26% to $65.0 million in 2023, then rose by 3.47% to $67.3 million in 2024.
  • Per Business Quant, the three most recent readings for ACIU's Non-Current Assets are $67.3 million (Q4 2024), $65.0 million (Q4 2023), and $60.0 million (Q4 2022).